Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CB699
- Development stage
- Preclinical
- Lead developer
- Crescendo Biologics
- Modality
- Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
01
Overview
CB699 is a half-life extended, trispecific multi-specific antibody developed by Crescendo Biologics. It targets three proteins—CD40 (tumor necrosis factor receptor superfamily member 5), CD137 (also known as 4-1BB, tumor necrosis factor receptor superfamily member 9), and mesothelin (MSLN). The molecule is designed to act as a dual agonist for CD40 and CD137 in a mesothelin-directed manner, conditionally activating T cells and antigen-presenting cells (APCs) only in the presence of MSLN+ tumor cells. This conditional activation aims to provide potent anti-cancer immune responses while minimizing off-tumor toxicity. Preclinical data show that CB699 can drive both CD40 and CD137 agonism depending on the cellular context, enhancing immune cell signaling axes for comprehensive anti-tumor activity[1][6][8]. The drug is currently in preclinical development for the treatment of mesothelin-positive neoplasms.
- Other names
- CB-699CB699CB 699
02
Targets
MesothelinTNFRSF9 (CD137 extracellular domain)CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on CB699.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CB699.